Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 1, 2004, Pages 23-37

  Zanger, Ulrich M ^a   Raimundo, Sebastian ^a   Eichelbaum, Michel ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Cytochrome P450; Drug metabolism; Drug oxidation polymorphism; Intermediate metabolizer; Pharmacogenetics; Pharmacogenomics; Ultrarapid metabolizer

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; APRINDINE; ATOMOXETINE; BUFURALOL; CLOMIPRAMINE; CODEINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; ENCAINIDE; ETHYLMORPHINE; FLECAINIDE; GALANTAMINE; HALOPERIDOL; HYDROCODONE; IMIPRAMINE; METOPROLOL; MEXILETINE; NICERGOLINE; NORCODEINE; NORTRIPTYLINE; OXYCODONE; PRAJMALINE; PROCAINAMIDE; PROPAFENONE; SPARTEINE; UNINDEXED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; CATALYSIS; CATALYST; CHROMOSOME 22; CHROMOSOME DELETION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; FIRST PASS EFFECT; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MENTAL DISEASE; MODEL; MOLECULAR GENETICS; NULL ALLELE; OPEN READING FRAME; PHARMACOGENETICS; PHARMACOPHORE; PHENOTYPE; PROMOTER REGION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SIDE EFFECT; TISSUE DISTRIBUTION; TISSUE LEVEL; TREATMENT OUTCOME;

ALLELES; ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; HUMANS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 0742286803     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0832-2     Document Type: Review

References (147)

1. Agundez JA, Ledesma MC, Ladero JM, Benitez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265-269
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446
3. Arcavi L, Benowitz NL (1993) Clinical significance of genetic influences on cardiovascular drug metabolism. Cardiovasc Drugs Ther 7:311-324
4. Armstrong M, Idle JR, Daly AK (1993) A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Hum Genet 91:616-617
5. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 2:1213-1216
6. Bathum L, Johansson I, Ingelman-Sundberg M, Horder M, Brosen K (1998) Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 8:119-123
7. Baumann P, Rochat B (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10 [Suppl 1]:15-21
8. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schulz HU, Sjoqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27:1673-1677
9. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478-480
10. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63
11. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-218
12. Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO (1996) Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Eur J Drug Metab Pharmacokinet 21: 309-314
13. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438-452
14. Broly F, Meyer UA (1993) Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 3:123-130
15. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384
16. Brosen K, Gram LF (1989) Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537-547
17. Brosen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60:312-314
18. Caporaso N, DeBaun MR, Rothman N (1995) Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 5:S129-S134
19. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M (1996) CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 91:149-159
20. Cesaro C, Raimundo S, Klein K, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2003) CYP2D6 "Intermediate Metabolizer" phenotype as a consequence of genetically determined alternative splicing. Chem. Listy, Symposia, 97 (2003), Abstract TP41, S137
21. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534
22. Chou WH, Yan FX, de Leon J, Bamhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246-251
23. Chou WH, Yan FX, Robbins-Weilert DK, Ryder B, Liu WW, Perbost C, Fairchild M, De Leon J, Koch WH, Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542-551
24. Christensen PM, Gotzsche PC, Brosen K (1997) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51:389-393
25. Christensen PM, Gotzsche PC, Brosen K (1998) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 8:473-479
26. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157-167
27. Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470
28. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995a) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520
29. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L (1995b) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159-164
30. Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63: 444-452
31. Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17:27-41
32. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996a) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
33. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM (1996b) Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6:319-328
34. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996c) CYP2D6 multiallelism. Methods Enzymol 272:199-210
35. Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7:73-77
36. Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) - increased Michaelis Constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 125:374-380
37. Dehal SS, Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406
38. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067
39. Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE et al (1999) The DNA sequence of human chromosome 22. Nature 402:489-495
40. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 46:377-394
41. Eichelbaum M, Woolhouse NM (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 28:79-83
42. Eichelbaum M, Spannbrucker N, Dengler HJ (1975) Lack of N-oxidation of sparteine in certain healthy subjects. Proceedings of the 6th International Congress of Pharmacology, Helsinki, July 20-25, p 1071
43. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187
44. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31:184-186
45. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22:49-53
46. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 23:455-458
47. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, Lennard MS, Tucker GT et al (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270:29055-29058
48. Endrizzi K, Fischer J, Klein K, Schwab M, Nüssler AC, Neuhaus P, Eichelbaum M, Zanger UM (2002) Discriminative quantification of CYP2D6 and CYP2D7/8 pseudogene mRNA by Taq-Man real-time reverse transcriptase-PCR in human liver. Anal Biochem 300:121-131
49. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491
50. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR (1989) Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 45:568-573
51. 324Pro) Expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedebergs Arch Pharmacol 355:309-318
52. Fonne-Pfister R, Bargetzi MJ, Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson's disease, is apotent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144-1150
53. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303-308
54. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48: 943-950
55. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [in process citation]. Pharmacogenetics 9:669-682
56. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27: 111-125
57. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988a) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446
58. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA (1988b) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2:174-179
59. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773-776
60. Gram LF, Brosen K (1993) Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. Br J Clin Pharmacol 35:649-652
61. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stüven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26
62. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population [in process citation]. Pharmacogenetics 9:715-723
63. Griese EU, Ilett KF, Kitteringham NR, Eichelbaum M, Powell H, Spargo RM, LeSouef PN, Musk AW, Minchin RF (2001) Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics 11:69-76
64. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA (2002) Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41:11025-11034
65. Guengerich FP, Hanna IH, Martin MV, Gillam EM (2003) Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 42:1245-1253
66. Guidice JM, Marez D, Sabbagh N, Legrand-Andreoletti M, Spire C, Alcaide E, Lafitte JJ, Broly F (1997) Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 241:79-85
67. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA (1986) Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261:11734-11743
68. Haefeli WE, Bargetzi MJ, Follath F, Meyer UA (1990) Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 15: 776-779
69. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47:994-1001
70. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
71. Hiratsuka M, Agatsuma Y, Omori F, Narahara K, Inoue T, Kishikawa Y, Mizugaki M (2000) High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol Pharm Bull 23:1131-1135
72. Hiroi T, Imaoka S, Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249: 838-843
73. Huang Z, Fasco MJ, Kaminsky LS (1997) Alternative splicing of CYP2D mRNA in human breast tissue. Arch Biochem Biophys 343:101-108
74. Idle JR, Corchero J, Gonzalez FJ (2000) Medical implications of HGP's sequence of chromosome 22. Lancet 355:319
75. Ingelman-Sundberg M (1999) Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 31:449-459
76. Ingelman-Sundberg M, Oscarson M (2002) Human CYP allele database: submission criteria procedures and objectives. Methods Enzymol 357:28-36
77. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW (2000) Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10:91-93
78. Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 22:541-550
79. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
80. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459
81. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355
82. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214
83. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS (1982) Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 13:637-645
84. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811
85. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904
86. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation- specific dosages. Acta Psychiatr Scand 104:173-192
87. Kivistö KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S
88. Kivistö KT, Griese EU, Stüven T, Fritz P, Friedel G, Kroemer HK, Zanger UM (1997) Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7:295-302
89. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, Donne-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219
90. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28-33
91. Kronbach T (1991) Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol 206:509-517
92. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G (1996) Gene-environment interaction in Parkinson's disease. The case of CYP2D6 gene polymorphism. Adv Neurol 69:61-72
93. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541
94. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558-1560
95. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
96. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11:45-55
97. Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327-338
98. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 16:1199-1205
99. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-256
100. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202
101. Martinez C, Agundez JA, Gervasini G, Martin R, Benitez J (1997) Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7:85-93
102. Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51:117-122
103. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187-191
104. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671
105. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296
106. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF (2002) Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 82:1376-1387
107. Molden E, Johansen PW, Boe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G (2002) Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 72:333-342
108. Murphy GM Jr, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, Reynolds CF III (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25:737-743
109. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034-1040
110. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027
111. Prueksaritanont T, Dwyer LM, Cribb AE (1995) (+)-Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 50:1521-1525
112. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581
113. Raimundo S, Fischer J, Eichelbaum M, Schwab M, Zanger UM (2003) A novel intronic SNP (2988 G>A) directly identifies the common "intermediate metabolizer" allele CYP2D6*41 (submitted).
114. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12:465-472
115. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A, Anttila S (1998) Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 20:465-469
116. Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA (1994) Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 15:1955-1961
117. Roots I, Brockmoller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 70:307-319
118. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8:227-238
119. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
120. Schaeffeler E, Schwab M, Eichelbaum M, Zanger M (2003) CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (in press)
121. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624
122. Shin JG, Soukhova N, Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078-1084
123. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245
124. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287
125. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240-5243
126. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51:395-398
127. Steen VM, Molven A, Aarskog NK, Gulbrandsen AK (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 4:2251-2257
128. Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394-401
129. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F (1988) Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431-435
130. Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM (1996) Rapid detection of CYP2D6 null alleles by long distance-and multiplex- polymerase chain reaction. Pharmacogenetics 6:417-421
131. Syvalahti EK, Lindberg R, Kallio J, De Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89-92
132. Thum T, Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979-983
133. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32
134. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353
135. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, Baumann P (2000) Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855:235-243
136. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418
137. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (London) 424:464-468
138. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45:2116-2122
139. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, Werner D, Eschenhagen T (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72: 429-437
140. Yamazaki S, Sato K, Suhara K, Sakaguchi M, Mihara K, Omura T (1993) Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem (Tokyo) 114:652-657
141. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ (1993) Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263
142. Yu A, Kneller BM, Rettie AE, Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300
143. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ (2003a) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173-181
144. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ (2003b) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319
145. Zanger UM, Vilbois F, Hardwick JP, Meyer UA (1988a) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-5454
146. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA (1988b) Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256-8260
147. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585